These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 29162523)

  • 1. Specific visualization of neuromelanin-iron complex and ferric iron in the human post-mortem substantia nigra using MR relaxometry at 7T.
    Lee H; Baek SY; Chun SY; Lee JH; Cho H
    Neuroimage; 2018 May; 172():874-885. PubMed ID: 29162523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Neuromelanin-related T2* Contrast in Postmortem Human Substantia Nigra with 7T MRI.
    Lee JH; Baek SY; Song Y; Lim S; Lee H; Nguyen MP; Kim EJ; Huh GY; Chun SY; Cho H
    Sci Rep; 2016 Sep; 6():32647. PubMed ID: 27596274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
    Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease.
    Pyatigorskaya N; Magnin B; Mongin M; Yahia-Cherif L; Valabregue R; Arnaldi D; Ewenczyk C; Poupon C; Vidailhet M; Lehéricy S
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1460-1467. PubMed ID: 29954816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability.
    Zucca FA; Bellei C; Giannelli S; Terreni MR; Gallorini M; Rizzio E; Pezzoli G; Albertini A; Zecca L
    J Neural Transm (Vienna); 2006 Jun; 113(6):757-67. PubMed ID: 16755380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
    He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM
    Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI T
    Lee H; Baek SY; Kim EJ; Huh GY; Lee JH; Cho H
    Neuroimage; 2020 May; 211():116625. PubMed ID: 32058001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease related signal change in the nigrosomes 1-5 and the substantia nigra using T2* weighted 7T MRI.
    Schwarz ST; Mougin O; Xing Y; Blazejewska A; Bajaj N; Auer DP; Gowland P
    Neuroimage Clin; 2018; 19():683-689. PubMed ID: 29872633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease.
    Lehéricy S; Bardinet E; Poupon C; Vidailhet M; François C
    Mov Disord; 2014 Nov; 29(13):1574-81. PubMed ID: 25308960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain.
    Zecca L; Shima T; Stroppolo A; Goj C; Battiston GA; Gerbasi R; Sarna T; Swartz HM
    Neuroscience; 1996 Jul; 73(2):407-15. PubMed ID: 8783258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-echo-time magnitude image derived from quantitative susceptibility mapping could resemble neuromelanin-sensitive MRI image in substantia nigra.
    Liu XL; Yang LQ; Liu FT; Wu PY; Zhang Y; Zhuang H; Shi YH; Wang J; Geng DY; Li YX
    BMC Neurol; 2020 Jun; 20(1):262. PubMed ID: 32605601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
    Wang C; Fan G; Xu K; Wang S
    Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automatic Segmentation and Quantification of Nigrosome-1 Neuromelanin and Iron in MRI: A Candidate Biomarker for Parkinson's Disease.
    Ariz M; Martínez M; Alvarez I; Fernández-Seara MA; Castellanos G; ; Pastor P; Pastor MA; Ortiz de Solórzano C
    J Magn Reson Imaging; 2024 Aug; 60(2):534-547. PubMed ID: 37915245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substantia nigra locations of iron-content, free-water and mean diffusivity abnormalities in moderate stage Parkinson's disease.
    Arribarat G; Pasternak O; De Barros A; Galitzky M; Rascol O; Péran P
    Parkinsonism Relat Disord; 2019 Aug; 65():146-152. PubMed ID: 31182373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast mechanisms associated with neuromelanin-MRI.
    Trujillo P; Summers PE; Ferrari E; Zucca FA; Sturini M; Mainardi LT; Cerutti S; Smith AK; Smith SA; Zecca L; Costa A
    Magn Reson Med; 2017 Nov; 78(5):1790-1800. PubMed ID: 28019018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring the iron content of dopaminergic neurons in substantia nigra with MRI relaxometry.
    Brammerloh M; Morawski M; Friedrich I; Reinert T; Lange C; Pelicon P; Vavpetič P; Jankuhn S; Jäger C; Alkemade A; Balesar R; Pine K; Gavriilidis F; Trampel R; Reimer E; Arendt T; Weiskopf N; Kirilina E
    Neuroimage; 2021 Oct; 239():118255. PubMed ID: 34119638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroimaging Correlates of Substantia Nigra Hyperechogenicity in Parkinson's Disease.
    Prasuhn J; Strautz R; Lemmer F; Dreischmeier S; Kasten M; Hanssen H; Heldmann M; Brüggemann N
    J Parkinsons Dis; 2022; 12(4):1191-1200. PubMed ID: 35180131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.